Avaí Bio, Inc. (OTCQB: AVAI) ("Avaí" or the "Company") and its joint venture partner Austrianova, today announced the first joint steering committee meeting for their collaboration with Ospedale San Raffaele S.r.l. (OSR), to discuss the initial research program for evaluating an encapsulated beta-cell replacement approach for insulin-dependent diabetes.
Login to comment